Affordable Access

deepdyve-link
Publisher Website

A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.

Authors
  • Tong, Gary
  • Wang, Jun-Sheng
  • Sverdlov, Oleksandr
  • Huang, Shu-Pang
  • Slemmon, Randy
  • Croop, Robert
  • Castaneda, Lorna
  • Gu, Huidong
  • Wong, Oi
  • Li, Hewei
  • Berman, Robert M
  • Smith, Christina
  • Albright, Charles F
  • Dockens, Randy
Type
Published Article
Journal
British Journal of Clinical Pharmacology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Jan 01, 2013
Volume
75
Issue
1
Pages
136–145
Identifiers
DOI: 10.1111/j.1365-2125.2012.04339.x
PMID: 22616739
Source
Medline
License
Unknown

Abstract

The favourable safety profile and pharmacokinetic effects of avagacestat in this study support its continued development, especially in the target population of elderly subjects with mild cognitive impairment or Alzheimer's disease.

Report this publication

Statistics

Seen <100 times